Search
Propacetamol
go.drugbank.com/drugs/DB09288InvestigationalPropacetamol is a non-opioid analgesic devoid of the major contraindications. It is a derivative of acetaminophen, or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parentera...
Mebutizide
go.drugbank.com/drugs/DB13430ExperimentalCategories: Low-Ceiling Diuretics and Potassium-Sparing AgentsSeletracetam
go.drugbank.com/drugs/DB05885InvestigationalIt is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S.
Cicletanine
go.drugbank.com/drugs/DB12766InvestigationalCicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.
Categories: Low-Ceiling Diuretics, Excl. ThiazidesFK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Omburtamab
go.drugbank.com/drugs/DB15635InvestigationalCD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for us...
Thymoquinone
go.drugbank.com/drugs/DB16447InvestigationalThymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
Iopentol
go.drugbank.com/drugs/DB13861ExperimentalIopentol is used as a contrast medium.
Categories: Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast MediaAcepromazine
go.drugbank.com/drugs/DB01614InvestigationalVet approvedAcepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...